Project Grant HT94252410157
Award Date
4/15/24
Completion Date
4/14/26
Dollars Obligated
$2.5M
Federal Agency
Defense Health Agency
Awardee
Kalocyte Inc. (MJMKM31FM667)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This $8,042,749 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding research at The Ohio State University to enhance the safety and efficacy of low-titer Group O whole blood. The research involves determining optimal concentrations of hemopexin, haptoglobin, and transferrin to neutralize hemolytic byproducts during ex vivo storage of whole blood units. The project includes testing this protein...
This three-year, $1.977 million Project Grant from the Department of the Army Medical Command will support Cytosorbents Medical Inc.'s demonstration of the safety and efficacy of its field-ready blood group antibody (BGA) adsorber in a porcine universal transfusion model. The Military Medical Research and Development program (CFDA 12.420) aims to transform military and public health care through innovative biomedical research solutions for battlefield medicine. Under this award, Cytosorbents...
The U.S. Defense Health Agency awarded a $1,996,885 project grant under the Military Medical Research and Development program (CFDA 12.420) to Selsym Biotech Inc., a woman-owned small business. The funding supports the development of SYMCLOT, a synthetic platelet mimetic particle technology, to augment hemostasis for patients requiring extracorporeal support, such as those with battlefield injuries. Previous grants from the National Institutes of Health have also supported Selsym Biotech's...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $4,000,000.00 in funding to Medcura, Inc. in Riverdale, MD to expand the development and production of a biopolymer powder treatment for noncompressible torso hemorrhage. The research aims to improve health outcomes for military service members and the broader public by advancing this innovative medical technology. The award period extends from Aug 5,...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $385,536.00 to Epicentrx Inc. to develop and translate a multimodal therapeutic agent and medical countermeasure for the treatment of military-related toxic exposures. The award period is from September 1, 2024 to August 31, 2027. The primary research focus is on creating innovative solutions to address health challenges relevant to military personnel,...
This $3,055,695 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the University of Utah's research on developing GJA1-20K as a novel treatment for hemorrhagic shock. The goal is to minimize mitochondrial injury and mitigate ischemia-reperfusion injury. This 4-year project, running from April 2024 through April 2028, will advance innovative biomedical research with potential to improve health outcomes for...
The Department of the Army Medical Command awarded a $993,366 Project Grant to Augusta University Research Institute, Inc. under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2022 through September 2025 to modulate hemostasis and metabolic homeostasis in order to treat hemorrhagic shock. Through basic, applied, and advanced biomedical research, the Military Medical Research and Development program seeks to improve military and...
The Defense Health Agency awarded a $285,750 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Functional Circulation LLC in Lake Mills, WI. The grant supports research to develop a normothermic machine perfusion system to enhance retinal preservation of whole eye allografts, with the aim of improving treatments for absolute blindness. The project will be conducted over a 12-month period from November 1, 2024 to October 31, 2025. The Military Medical...
The Department of the Army Medical Command awarded Cayuga Biotech Inc. a $922,870 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will support Cayuga Biotech's development of an intravenous agent for traumatic hemorrhage control from July 1, 2021 to June 30, 2022. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions, including investigations into...
This Project Grant from the Defense Health Agency provides $734,781 to Formation Venture Engineering Foundry Inc. for precision medicine immunotherapy research under the Military Medical Research and Development program (CFDA 12.420). The research aims to develop medical solutions for treating neurodegeneration in amyotrophic lateral sclerosis patients who test positive for human endogenous retrovirus K. The awardee will conduct applied and advanced biomedical research from June 2023 through...